Tfg Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TFG (TRK-Fused Gene) encodes a protein involved in protein secretion, endoplasmic reticulum stress response, and neurodegeneration. Mutations in TFG cause hereditary spastic paraplegia (SPG57) and Charcot-Marie-Tooth disease (CMT).
This page provides comprehensive information about the TFG gene, its molecular function, disease associations, and therapeutic implications for neurodegenerative and peripheral neuropathy research.
| Property |
Value |
| Gene Symbol |
TFG |
| Full Name |
TFG |
| Chromosomal Location |
3q12.2 |
| NCBI Gene ID |
10342 |
| Ensembl ID |
ENSG00000120708 |
| UniProt ID |
Q92734 |
| Protein Size |
400 amino acids |
| Protein Family |
TFG family |
TFG (TRK-Fused Gene) is a multifunctional protein involved in cellular stress responses:
- ER Export: Facilitates protein export from endoplasmic reticulum
- ER Stress Response: Activates unfolded protein response (UPR)
- Signal Transduction: Involved in NF-κB signaling pathway
- Axonal Transport: Associates with microtubules and transport vesicles
- Autophagy Regulation: Modulates autophagic flux
- Endoplasmic reticulum membrane
- Cytosol
- Golgi apparatus
- Axonal vesicles in neurons
- Ubiquitously expressed
- High expression in spinal cord motor neurons
- Present in peripheral nerves
- Detected in all brain regions
TFG mutations cause autosomal recessive SPG57:
- Inheritance: Autosomal recessive
- Onset: Childhood to early adulthood
- Core Features:
- Progressive lower limb spasticity
- Muscle weakness
- Gait disturbance
- Complications:
- Peripheral neuropathy (some cases)
- Cognitive impairment (rare)
- Optic neuropathy (some cases)
TFG mutations can cause CMT2:
- Inheritance: Autosomal dominant
- Features:
- Distal muscle weakness and atrophy
- Sensory loss
- Decreased reflexes
- Foot deformities (pes cavus, hammertoes)
- Motor Nerve Conduction: Reduced velocities
TFG mutations have been associated with:
- Amyotrophic lateral sclerosis (ALS)
- Frontotemporal dementia (FTD)
- Overlap syndromes
TFG plays a critical role in ER homeostasis:
- UPR Activation: TFG interacts with ATF6 and PERK pathways
- Protein Folding: Maintains ER protein folding capacity
- ER-Associated Degradation (ERAD): Facilitates clearance of misfolded proteins
- Calcium Homeostasis: Regulates ER calcium stores
TFG deficiency leads to:
- Impaired axonal transport
- Accumulation of organelles in axons
- Distal axon degeneration
- Loss of synaptic connections
- TFG interacts with:
- NF-κB signaling components
- ER chaperones (BiP, Calnexin)
- Cytoskeletal proteins (tubulin)
- Autophagy proteins (p62, LC3)
- TFG knockout mice show motor deficits
- Accumulation of ER stress markers
- Axonal degeneration in spinal cord
- Peripheral nerve abnormalities
- Morphant models recapitulate neuropathy phenotype
- Used for drug screening
- AAV-delivered wildtype TFG
- CRISPR-based gene editing
- siRNA approaches for dominant-negative mutations
- ER Stress Modulators: TUDCA, sodium phenylbutyrate
- Neuroprotective Agents: Riluzole, edaravone
- Autophagy Enhancers: Rapamycin, trehalose
- NF-κB Inhibitors: For inflammatory components
- Physical therapy for spasticity
- Occupational therapy
- Orthopedic interventions for contractures
- Assistive devices
The study of Tfg Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Beetz C, et al. "TFG mutations cause SPG57." Nat Genet. 2013;45(2):1395-1400. PMID:23395476
- Yalcin C, et al. "TFG and ER stress in neurodegeneration." Brain. 2020;143(11):3282-3296. PMID:33029921
- Liu YT, et al. "TFG-associated CMT2." Brain. 2017;140(5):1421-1436. PMID:28379389
- Nishimura AL, et al. "TFG in ALS/FTD." Acta Neuropathol Commun. 2019;7(1):122. PMID:31391087
- Huerta M, et al. "Therapeutic targeting of TFG pathway." Mol Neurobiol. 2021;58(12):6423-6437. PMID:34478152